Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of subcutaneous vs intravenous frexalimab in multiple sclerosis
jRCT2031250826Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of frexalimab in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by Sanofi. Primary endpoints: AUCW20-W24 and Ctrough,SS. Started May 2026; status: recruiting.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on jRCT2031250826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250826.